This article is a correction to:
Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV–MCD) and the KSHV Inflammatory Cytokine Syndrome
Mark N. Polizzotto
Thomas S. Uldrick
Duosha Hu
Robert Yarchoan- HIV/AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States
by Polizzotto, M. N., Uldrick, T. S., Hu, D., and Yarchoan, R. (2012). Front. Microbiol. 3:73. doi: 10.3389/fmicb.2012.00073
In the original article, there was a mistake in Table 2 as published. The units for C reactive protein, ≥3 g/dL, were incorrect, and in fact, because different laboratories have different normal ranges for C reactive protein, we are not providing a specific value. The corrected Table 2 appears below.
TABLE 2
Table 2. Proposed working case definition of KSHV inflammatory cytokine syndrome.
In addition, the copyright should be considered inaccurate and has been removed to reflect the policies of the United States Government. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
The original article has been updated.
Conflict of Interest Statement
The spouse of one of the authors has patents on an assay to measure KSHV vIL-6. These inventions were made as a full-time employee of the US government under 45 Code of Federal Regulations Part 7. All rights, title, and interest to these patents have been assigned to the U.S. Department of Health and Human Services. The government conveys a portion of the royalties it receives to its employee inventors under the Federal Technology Transfer Act of 1986 (P.L. 99–502).
Keywords: Kaposi sarcoma-associated herpesvirus, human herpesvirus 8, multicentric Castleman disease, KSHV Inflammatory cytokine syndrome, interleukin-6, human immunodeficiency virus
Citation: Polizzotto MN, Uldrick TS, Hu D and Yarchoan R (2017) Corrigendum: Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV–MCD) and the KSHV inflammatory cytokine syndrome. Front. Microbiol. 8:1572. doi: 10.3389/fmicb.2017.01572
Received: 30 June 2017; Accepted: 03 August 2017;
Published: 21 August 2017.
Edited and reviewed by: Keiji Ueda, Osaka University, Japan
Copyright © 2017 This work is authored by Mark N. Polizzotto, Thomas S. Uldrick, Duosha Hu and Robert Yarchoan on behalf of the U.S. Government and, as regards Drs. Polizzotto, Uldrick, Hu and Yarchoan and the US government, is not subject to copyright protection in the United States. Foreign and other copyrights may apply. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Robert Yarchoan, robert.yarchoan@nih.gov